Tag: Drugs and Pharmaceuticals
BioTE Medical Study Showing Promising Results for Military Veterans Diagnosed with PTSD and TBI
IRVING, Texas, Dec. 30, 2015 (SEND2PRESS NEWSWIRE) -- A current BioTE(R) Medical Combat Trauma Treatment Study (in conjunction with the Veterans Advocacy Center (VAC)) is showing promising results in helping veterans suffering from Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).
Weitz and Luxenberg Adds Serious Urinary Tract Infections to SGLT2 Inhibitor Injuries Probe
NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.
Harbor Compounding Pharmacy Advises About Coverage for Compounded Medications During Open Enrollment 2016
COSTA MESA, Calif., Oct. 12, 2015 (SEND2PRESS NEWSWIRE) -- Many insurance plans are dropping coverage of compounded medications, but some insurance plans still do cover for these custom formulations. Harbor Compounding Pharmacy provides resources and referrals to patients to find insurance coverage for their compounded medications during open enrollment 2016.
E-VAI – the Artificial Intelligence Platform from Eularis Changes the Rules of the Marketing in Pharma
NEW YORK, N.Y. and Tokyo, Sept. 15, 2015 (SEND2PRESS NEWSWIRE) -- Eularis announces today the release of E-VAI, the latest development in sophisticated artificial intelligence technology delivering next generation analytics and decision making to Pharma marketers globally. E-VAI changes the game for marketers struggling to understand and get value from their marketing.
Zofran Birth Defect Cases Being Accepted by Weitz and Luxenberg
NEW YORK, N.Y., April 7, 2015 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., announced it is accepting cases of congenital heart defects and cleft facial abnormalities in children whose mothers took the prescription drug Zofran during pregnancy to relieve symptoms of morning sickness.
Weitz & Luxenberg’s Relkin Appointed to Xarelto MDL Leadership Team
NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) -- Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs' steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.
CMI’s Paul Gondek and Alisa Hamilton to Co-Present with Deanna Schwarz of Pfizer at 2013 PRMG Annual National Conference
ATLANTA, Ga., March 7, 2013 (SEND2PRESS NEWSWIRE) -- CMI and Pfizer will co-present 'Engaging Stakeholders with A Story - 3 Tips to Improve Research Reporting' at the PMRG's upcoming National Annual Conference March 10-12 in National Harbor, Md.
